Last updated: February 20, 2026
What is NDC 59651-0152?
NDC 59651-0152 refers to a prescription drug approved by the FDA. According to the National Drug Code Directory, this identifier corresponds to Xyrem (sodium oxybate), used primarily for narcolepsy and cataplexy treatment. Xyrem is marketed by Jazz Pharmaceuticals. The drug is a Schedule III controlled substance with specific manufacturing, distribution, and prescribing regulations.
Market Overview
The Xyrem market is driven by its approved indications, limited competition, and regulatory constraints. The drug's primary competitors include lower-dose formulations, generics (if approved), and alternative narcolepsy treatments like modafinil or sodium oxybate alternatives.
Market Size and Demand
- US Approved Prescriptions: Approximately 20,000-25,000 patients annually.
- Growth Rate: The market exhibits a compound annual growth rate (CAGR) of approximately 4-6% driven by new diagnoses and expanding awareness.
- Market Penetration: Xyrem accounts for about 80% of the narcolepsy-specific medication market, with remaining share split among other drugs.
Key Market Drivers
- Increasing prevalence of narcolepsy, estimated at 135,000–200,000 cases in the US.
- Regulatory exclusivity granted until 2024, delaying generic entry.
- Growing awareness and diagnosis of narcolepsy.
Limitations and Risks
- Schedule III classification restricts prescribing and dispensing, impacting market penetration.
- Strict distribution through the Xyrem REMs restricted distribution program limits supply flexibility.
- Possible market erosion upon patent expiration and approval of generics.
Price Analysis
Current Pricing
- Average Wholesale Price (AWP): Around $116 per 5 mL vial.
- Cost per Month: Estimated at $4,700 for standard dosing (e.g., 4.5 g nightly).
- Patient Cost: Actual cost to patients varies significantly depending on insurance coverage, copay assistance, and manufacturer programs.
Pricing Trends
- Historically Stable: The wholesale price has remained relatively stable over the past five years, with minor annual increases (~2-3%).
- Negotiated Discounts: Insurance companies and PBMs often obtain negotiated rebates, reducing net prices.
Competitive Pricing and Margins
- Generic Entry: Currently, no generics are FDA-approved for Xyrem, providing pricing power to Jazz Pharmaceuticals.
- Potential Price Erosion: Forecasted after patent expiry, with generic versions expected to enter the market within 1-3 years post-expiry, potentially reducing prices by 60-70%.
Price Projections
| Year |
Estimated Wholesale Price per 5 mL vial |
Notes |
| 2023 |
$116 |
Current stabilized pricing |
| 2024 |
$118 |
Context of inflation and limited competition |
| 2025 |
$118-120 |
Before patent expiry, assuming no significant market disruptors |
| 2026 |
$50-70 (post-generic) |
Expected generic entry, significant price erosion anticipated |
| 2027+ |
Stabilized at $50-$70 |
Limited brand premium, generic market dominance predicted |
Note: These projections assume no significant regulatory or market changes. Price reduction scenarios depend on the pace of generic approval and market penetration.
Regulatory Outlook and Impact
- Patent Status: Patent expires in 2024, with data exclusivity until then.
- Generic Approval Outlook: The first generic applications could be submitted within 6-12 months pre-expiry, with approval following within 6-12 months afterward (per FDA guidelines).
- REMs Restrictions: May limit rapid market adoption of generics, delaying price erosion.
Strategic Considerations
- Market exclusivity provides a window for premium pricing.
- Preparations for generic competition include potential line extension (e.g., different doses), combination therapies, or new indications.
- Monitoring regulatory and legislative developments affecting Schedule III drugs, notably changes in REMs regulation or scheduling.
Key Takeaways
- NDC 59651-0152 (Xyrem) commands high wholesale prices with tight regulatory constraints.
- The market size remains stable, with limited competition due to regulatory and patent protections.
- Pricing is expected to decline sharply post-patent expiry, with generic entry projected around 2025-2026.
- The absence of generic competition until then allows for stable pricing and margins.
- Strategic planning should consider regulatory timelines, patent expiration, and potential market erosion.
FAQs
Q1: When is the patent for Xyrem set to expire?
A1: Patent protection is scheduled to expire in 2024, opening the door for generic competition.
Q2: How does REMs regulation affect the market?
A2: REMs restrict distribution and prescribing, limiting market accessibility and expansion opportunities.
Q3: What impact will generics have post-2025?
A3: Generics could reduce prices by up to 70%, significantly impacting revenue and market share.
Q4: Are there any recent regulatory changes affecting this drug?
A4: No recent regulatory changes; patent expiry remains the primary factor influencing future market dynamics.
Q5: How does insurance coverage impact patient access and pricing?
A5: Insurance and copay assistance programs mitigate out-of-pocket costs for patients but can affect net pricing and margins for manufacturers.
References
- Food and Drug Administration. (2023). FDA Approved Drugs Database. Retrieved from https://www.fda.gov
- IQVIA. (2022). National Prescription Audit.
- Jazz Pharmaceuticals. (2023). Xyrem Prescribing Information.
- U.S. Patent and Trademark Office. (2023). Patent Expiry Data.
- SSR Health. (2023). Pharmaceutical Market Data and Pricing Trends.
